This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

[video] Quick Take: Cramer on Mergers and Markets

NEW YORK ( TheStreet) -- TheStreet's Jim Cramer is with Debra Borchardt, answering the top questions from his Twitter feed.

Once again, there is big buyout in the biotech space, with Amgen (AMGN - Get Report) announcing a deal to acquire Onyx Pharmaceuticals (ONXX).

The deal is worth $10 billion, and Cramer said it made sense to pay this much for a company currently doing $2 billion in sales.

He added that Amgen used to be a great innovator and this deal will allow it to become a great biotech company again.

NASDAQ OMX Group (NDAQ - Get Report) continues to experience some fallout from last week's three-hour trading halt on its Nasdaq exchange.

"Nasdaq shut everybody down," said Cramer. "They basically said, 'Listen, what we did was good for retail, and being transparent was a mistake there,' and they got unchallenged, and all I can say is, 'Wow, they pulled it off again.'"

The Securities and Exchange Commission said it would look into testing some of the trading systems, but it did not mention anything about high-frequency trading, Borchardt said.

Cramer said you can't say anything negative about high-frequency trading, because if you do, "You run the risk of wrath."

He also said: "I don't think that high-frequency trading is a good thing, but ... they'll just say, 'Hey listen, how can you say that? You're against innovation; you're against financial engineering.' I am against things that hurt retail investors, but Nasdaq said what they did was pro retail investor, so I'd like to know more why that is, but that's what they said."

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, had no positions in the stocks mentioned.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONYX $0.00 0.00%
AMGN $163.58 0.00%
NDAQ $48.68 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs